Akari Therapeutics (AKTX) Interest Expenses (2014 - 2026)

Akari Therapeutics has disclosed Interest Expenses across 5 years of filings, most recently posting $61000.0 for Q1 2026.

• Interest Expenses for Q1 2026 came in at $61000.0, up 10.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (down 96.16% YoY), and the FY2025 annual result was $949000.0, up 31533.33% from the prior year.
• Interest Expenses came in at $61000.0 for Q1 2026 at Akari Therapeutics, down from $849000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $28.0 million in Q4 2024 to a low of $50000.0 in Q2 2025.
• The 3-year median for Interest Expenses is $65000.0 (2024), against an average of $3.7 million.
• Peak annual rise in Interest Expenses reached 75.36% in 2025, while the deepest fall reached 96.97% in 2025.
• Akari Therapeutics' Interest Expenses stood at $28.0 million in 2024, then sank by 96.97% to $849000.0 in 2025, then sank by 92.82% to $61000.0 in 2026.
• The last three Interest Expenses figures came in at $61000.0 (Q1 2026), $849000.0 (Q4 2025), and $121000.0 (Q3 2025), per Business Quant data.